(Date:12/3/2009)...nary Press Conference Topics, Last Call! Press F..., Attention PIOs: Sending Press Releases to Fall...dline 10 December, News Media registration infor...ration deadline THIS MONDAY, 7 December, Who,s c...visas for international reporters, please see: Med...
(Date:12/3/2009)...l snubbing? Your genetics, not your friends, may b...ium-like painkillers, called opioids, relieve not ...al stress. Now, a new study reviewed by Faculty of...l genetic differences in the gene for the opioid r...sponses to social rejection. , In the study pub...
(Date:12/3/2009)...lt that occurred during the 2008-09 austral summer...es for two main climate drivers, ENSO (El Nio - So...nnular Mode), according to Dr. Marco Tedesco, Assi... The City College of New York. , Professor Ted...UNY Graduate Center, added that Antarctic snowmelt...
Breaking Biology News(10 mins):AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 2AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 3AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 4AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 5AGU fall meeting: Preliminary press conference topics, press pre-registration deadline 6CCNY professor foresees rising Antarctic snowmelt 2American Council on Exercise 28ACE 29 Announces Top Ten Tips to Avoid the Freshman 15 54721 1American Council on Exercise 28ACE 29 Announces Top Ten Tips to Avoid the Freshman 15 54721 2American Council on Exercise 28ACE 29 Announces Top Ten Tips to Avoid the Freshman 15 54721 3Hanes 28R 29 and Susan G Komen for the Cure 28R 29 Inspire Creativity for a Cause 54718 1Hanes 28R 29 and Susan G Komen for the Cure 28R 29 Inspire Creativity for a Cause 54718 2Hanes 28R 29 and Susan G Komen for the Cure 28R 29 Inspire Creativity for a Cause 54718 3Hanes 28R 29 and Susan G Komen for the Cure 28R 29 Inspire Creativity for a Cause 54718 4Aethlon Medical to Present at Todays Southern California Investor Conference 54714 1Aethlon Medical to Present at Todays Southern California Investor Conference 54714 2(Date:12/1/2009)...ev., Dec. 1 PDL BioPharm...enue guidance for the fourth quarter ended Decembe...ed with $69 million for the fourth quarter of 2008...first of two installment payments of $12.5 million...08 results was a one-time $1.8 million payment fro...
(Date:12/1/2009)...ec. 1 Reportlinker.com announces t...ts catalogue: ,, Industrial Enzymes - A Global.../p0164431/Industrial-Enzymes---A-Global-Market-Rep...igopoly with few strong players and a host of smal...en competition and commoditization characterize th...
(Date:12/1/2009)...Dec. 1 Harvest Technologies Corp. ...om the company sponsored 60-patient clinical trial...ennai, India using the company,s BMAC System to tr...b Ischemia (CLI). Sri Ramachandra Medical Center i...tution based in Chennai, India and one of the larg...
(Date:12/1/2009)...ity Leader Richard Gephardt Brings Together A-List...unities for "Best and Brightest Forum on Medical ...ewswire-USNewswire/ -- Several of New Jersey,s mos...h, medicine and technology gathered today at the L... medical innovation in New Jersey, and throughout ...
Breaking Biology Technology:PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Reportlinker Adds Industrial Enzymes - A Global Market Report 2Reportlinker Adds Industrial Enzymes - A Global Market Report 3Reportlinker Adds Industrial Enzymes - A Global Market Report 4Reportlinker Adds Industrial Enzymes - A Global Market Report 5Reportlinker Adds Industrial Enzymes - A Global Market Report 6Reportlinker Adds Industrial Enzymes - A Global Market Report 7Reportlinker Adds Industrial Enzymes - A Global Market Report 8Reportlinker Adds Industrial Enzymes - A Global Market Report 9Reportlinker Adds Industrial Enzymes - A Global Market Report 10Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5...if., Feb. 7 Neurobiological,Technologies, Inc. (N...elease,its second quarter 2008 financial results, ...ry 11. The Company will host a conference call to,...e., Hosting the call will be Paul E. Freiman, Pre...arlson, Vice President and Chief Financial Officer...
...and MONROVIA, Calif., Feb. 7 ,Human Genome Science...nounced,a collaboration agreement under which Xenc...n and optimization technologies to enhance the,pha...eloped by HGS that,specifically target antigens di...cgi-bin/prnh/20010612/HGSLOGO ), "The priority f...
....Y., Feb. 7 Bunge Limited,(NYSE: BG ), -- Tota...ared to the same quarter last year, -- Agribu...tions, posting 14% volume growth in the quarte...ed farm economics and high international price... share data and percentages), ...
Other Biology Technology:Human Genome Sciences and Xencor Announce Antibody Collaboration 2Human Genome Sciences and Xencor Announce Antibody Collaboration 3Human Genome Sciences and Xencor Announce Antibody Collaboration 4Bunge Reports Fourth Quarter Net Income of $245 Million 2Bunge Reports Fourth Quarter Net Income of $245 Million 3Bunge Reports Fourth Quarter Net Income of $245 Million 4Bunge Reports Fourth Quarter Net Income of $245 Million 5Bunge Reports Fourth Quarter Net Income of $245 Million 6Bunge Reports Fourth Quarter Net Income of $245 Million 7Bunge Reports Fourth Quarter Net Income of $245 Million 8Bunge Reports Fourth Quarter Net Income of $245 Million 9Bunge Reports Fourth Quarter Net Income of $245 Million 10Bunge Reports Fourth Quarter Net Income of $245 Million 11Bunge Reports Fourth Quarter Net Income of $245 Million 12Bunge Reports Fourth Quarter Net Income of $245 Million 13Bunge Reports Fourth Quarter Net Income of $245 Million 14Bunge Reports Fourth Quarter Net Income of $245 Million 15Bunge Reports Fourth Quarter Net Income of $245 Million 16Bunge Reports Fourth Quarter Net Income of $245 Million 17Bunge Reports Fourth Quarter Net Income of $245 Million 18Bunge Reports Fourth Quarter Net Income of $245 Million 19Bunge Reports Fourth Quarter Net Income of $245 Million 20The Discovery Series PDQuest Version Upgrade from Bio-Rad
Mouse Anti-Human ARHGEF11 Monoclonal Antibody, Unconjugated, Clone 2F4 from Abnova Corporation
Mouse Anti-Human MYO7A Monoclonal Antibody, Unconjugated, Clone 1D3 from Abnova Corporation
... ,High Quality, Functionally-Validated, Ion Channe...ving a critical role in nerve and muscle function ...and the heart. Drugs that modulate ion channels ha... neuropathic pain, cardiac arrhythmia, hypertensio...
Biology Products: